Islet Sciences, Inc., (OTC.BB: ISLT) a biotechnology company engaged in development and commercialization of patented technologies for the next generation of therapy for persons with Diabetes, today announced that Dr. Eitan Akirav has joined its Scientific Advisory Board. “This key addition to our Scientific Advisory Board is a testament to the solid progress we have made and the leading edge therapies for diabetes that we are focused on providing,” stated Dr. Jonathan Lakey, Chief Scientific Officer and Chairman of the Scientific Advisory Board of Islet Sciences. “As we bolster our overall team we are proud to add Dr. Akirav to our organization and look forward to announcing additional milestones over the coming year.” “I am pleased to announce this strategic addition to our Scientific Advisory Board as we continue to make significant progress on our growth strategy,” said John Steel, Chairman and CEO of Islet Sciences. “The expertise and deep industry relationships Dr. Akirav brings along with his significant knowledge in the field of diabetes will be quite helpful to the company moving forward. Dr. Akirav’s recent co-authorship of the American Diabetes Association study titled “Immune Therapy and β-Cell Death in Type 1 Diabetes” is clearly groundbreaking and we are thrilled that he has chosen to be a part of our esteemed Scientific Advisory Board.” Dr. Akirav stated, “My laboratory is involved in the development of new diagnostic assays for the detection of β cell loss in diabetes. By joining Islet Sciences’ Scientific Advisory Board I hope to deepen our collaboration and advance the company’s mission towards finding a cure for Type 1 Diabetes.” Dr. Eitan Akirav is a Research Scientist at Winthrop-University Hospital and an Assistant Professor of Research at Stony Brook University School of Medicine in Long Island, NY. His novel work in the field of diabetes mellitus includes the development of a method for measuring dead β cell DNA in the blood. Together with Dr. Kevan Herold of Yale University, Dr. Akirav’s method provides, for the first time, a real time measurement of β cell loss during the phases of pre-diabetes, disease diagnosis, and following clinical intervention. In addition, Dr. Akirav focuses on understanding the interactions between β cells and the islet endothelium, while identifying novel factors that can improve β cell function and promote cell regeneration. Dr. Akirav collaborates with colleagues at numerous global institutions. He received a B.Sc. from Tel Aviv University (Summa Cum Laude), a M.Sc. from the University of Toronto, and a Ph.D. and postdoctoral training from Yale University. During his academic training, Dr. Akirav focused on autoimmune diseases, such as multiple sclerosis and Type 1 diabetes.